SS
AMLX icon

Steve Schonfeld’s Amylyx Pharmaceuticals AMLX Stock Holding History

Steve Schonfeld’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Sell
66,804
-10,990
-14% -$170K ﹤0.01% 1371
2026
Q1 		$1.08M Buy
77,794
+56,742
+270% +$798K 0.01% 1054
2025
Q4 		$254K Sell
21,052
-22,585
-52% -$307K ﹤0.01% 1627
2025
Q3 		$593K Sell
43,637
-602,806
-93% -$5.67M ﹤0.01% 1620
2025
Q2 		$4.14M Buy
646,443
+529,303
+452% +$2.57M 0.03% 629
2025
Q1 		$415K Sell
117,140
-76,791
-40% -$273K ﹤0.01% 1662
2024
Q4 		$733K Buy
193,931
+27,502
+17% +$129K ﹤0.01% 1252
2024
Q3 		$539K Buy
166,429
+144,829
+671% +$326K ﹤0.01% 1401
2024
Q2 		$41K Buy
+21,600
New +$41.9K ﹤0.01% 1953
2023
Q4 		– Sell
-137,523
Closed -$2.52M – 1848
2023
Q3 		$2.52M Sell
137,523
-72,862
-35% -$1.54M 0.02% 754
2023
Q2 		$4.54M Sell
210,385
-74,620
-26% -$2.02M 0.04% 516
2023
Q1 		$8.36M Buy
285,005
+173,081
+155% +$6.01M 0.08% 328
2022
Q4 		$4.14M Sell
111,924
-213,776
-66% -$7.59M 0.03% 541
2022
Q3 		$9.17M Buy
+325,700
New +$8.13M 0.08% 340

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Steve Schonfeld's AMLX Position: Q2 2026 in Review

Steve Schonfeld reduced its Amylyx Pharmaceuticals (AMLX) stake by 14% in Q2 2026, selling an estimated $170K and leaving 66,804 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1371.

Steve Schonfeld first reported a position in AMLX in Q3 2022 and has held it in 14 quarters since. The position peaked at $9.17M in Q3 2022. 205 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Steve Schonfeld held 66,804 shares of Amylyx Pharmaceuticals worth $1.2M as of Q2 2026.
  • Steve Schonfeld sold 10,990 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $170K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Steve Schonfeld's portfolio in Q2 2026, its #1371 holding.
  • Steve Schonfeld first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 14 quarters since.
  • Steve Schonfeld's Amylyx Pharmaceuticals position peaked at $9.17M in Q3 2022.
  • 205 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.